Spots Global Cancer Trial Database for Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL
Official Title: Treatment of Elderly Relapsed and/or Refractory CD19-positive Acute Lymphoblastic Leukemia by Infusions of Allogeneic CART-19
Study ID: NCT02799550
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and efficiency of allogeneic cluster of differentiation 19 (CD19)-directed chimeric antigen receptor modified T cells (CART-19) infusions in patients with relapsed / refractory B-cell acute lymphoblastic leukemia (B-ALL)
Detailed Description: The relapsed and/or refractory B-ALL patients will receive infusions of allogeneic CART-19 within 1 week after chemotherapy. The re-induction chemotherapy regimen was primarily vindesine, mitoxantrone, cyclophosphamide, pegaspargase and dexamethasone, and no graft-versus-host disease (GVHD) prevention was conducted pre- and post- therapy.
Keywords
Eligibility
Minimum Age: 60 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Affiliated Hospital of Academy of Military Medical Sciences ,, Beijing, Beijing, China
Chinese PLA General Hospital, Beijing, Beijing, China
Contact Details
Name: Huisheng Ai, MD
Affiliation: Affiliated Hospital of Academy of Military Medical Sciences
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
